Hikma Pharmaceuticals' market value is the price at which a share of Hikma Pharmaceuticals trades on a public exchange. It measures the collective expectations of Hikma Pharmaceuticals PLC investors about its performance. Hikma Pharmaceuticals is trading at 26.64 as of the 1st of February 2025. This is a 0.53 percent increase since the beginning of the trading day. The stock's lowest day price was 26.64. With this module, you can estimate the performance of a buy and hold strategy of Hikma Pharmaceuticals PLC and determine expected loss or profit from investing in Hikma Pharmaceuticals over a given investment horizon. Check out Hikma Pharmaceuticals Correlation, Hikma Pharmaceuticals Volatility and Hikma Pharmaceuticals Alpha and Beta module to complement your research on Hikma Pharmaceuticals.
Please note, there is a significant difference between Hikma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hikma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hikma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Hikma Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Hikma Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Hikma Pharmaceuticals.
0.00
08/05/2024
No Change 0.00
0.0
In 5 months and 30 days
02/01/2025
0.00
If you would invest 0.00 in Hikma Pharmaceuticals on August 5, 2024 and sell it all today you would earn a total of 0.00 from holding Hikma Pharmaceuticals PLC or generate 0.0% return on investment in Hikma Pharmaceuticals over 180 days. Hikma Pharmaceuticals is related to or competes with Porvair Plc, AerSale Corp, Ryanair Holdings, Verde Clean, HF Sinclair, Pentair PLC, and Wheels Up. Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharma... More
Hikma Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Hikma Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Hikma Pharmaceuticals PLC upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hikma Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Hikma Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Hikma Pharmaceuticals historical prices to predict the future Hikma Pharmaceuticals' volatility.
At this point, Hikma Pharmaceuticals is very steady. Hikma Pharmaceuticals PLC holds Efficiency (Sharpe) Ratio of 0.062, which attests that the entity had a 0.062 % return per unit of risk over the last 3 months. We have found twenty-one technical indicators for Hikma Pharmaceuticals PLC, which you can use to evaluate the volatility of the firm. Please check out Hikma Pharmaceuticals' Standard Deviation of 1.83, market risk adjusted performance of 6.64, and Risk Adjusted Performance of 0.0549 to validate if the risk estimate we provide is consistent with the expected return of 0.12%. Hikma Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0148, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Hikma Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Hikma Pharmaceuticals is expected to be smaller as well. Hikma Pharmaceuticals PLC right now retains a risk of 1.92%. Please check out Hikma Pharmaceuticals total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Hikma Pharmaceuticals will be following its current trending patterns.
Auto-correlation
-0.38
Poor reverse predictability
Hikma Pharmaceuticals PLC has poor reverse predictability. Overlapping area represents the amount of predictability between Hikma Pharmaceuticals time series from 5th of August 2024 to 3rd of November 2024 and 3rd of November 2024 to 1st of February 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Hikma Pharmaceuticals PLC price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Hikma Pharmaceuticals price fluctuation can be explain by its past prices.
Correlation Coefficient
-0.38
Spearman Rank Test
0.16
Residual Average
0.0
Price Variance
1.13
Hikma Pharmaceuticals PLC lagged returns against current returns
Autocorrelation, which is Hikma Pharmaceuticals pink sheet's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Hikma Pharmaceuticals' pink sheet expected returns. We can calculate the autocorrelation of Hikma Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Hikma Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the pink sheet is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values
Timeline
Hikma Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Hikma Pharmaceuticals pink sheet is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Hikma Pharmaceuticals pink sheet is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Hikma Pharmaceuticals pink sheet over time.
Current vs Lagged Prices
Timeline
Hikma Pharmaceuticals Lagged Returns
When evaluating Hikma Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Hikma Pharmaceuticals pink sheet have on its future price. Hikma Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Hikma Pharmaceuticals autocorrelation shows the relationship between Hikma Pharmaceuticals pink sheet current value and its past values and can show if there is a momentum factor associated with investing in Hikma Pharmaceuticals PLC.
Other Information on Investing in Hikma Pink Sheet
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.